- Home
- XCUR vs ITRM Comparison
XCUR vs ITRM Comparison
Compare XCUR & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XCUR | ITRM |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.8M | 24.3M |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | XCUR | ITRM |
|---|---|---|
| Price | $4.06 | $0.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 19.9K | ★ 1.1M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $947.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.10 | $0.14 |
| 52 Week High | $15.87 | $1.49 |
Technical Indicators
Market Signals| Indicator | XCUR | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 48.85 | 34.51 |
| Support Level | $3.47 | N/A |
| Resistance Level | $4.23 | $0.39 |
| Average True Range (ATR) | 0.26 | 0.03 |
| MACD | 0.09 | -0.01 |
| Stochastic Oscillator | 73.32 | 15.46 |
Price Performance
Historical ComparisonAbout XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.